Browse > Article
http://dx.doi.org/10.5352/JLS.2012.22.11.1456

Development and Validation of the Determination of Sorafenib in Human Plasma using Tandem Mass Spectrometry Coupled with Liquid Chromatography  

Park, Daejin (Department of Pharmacology, Kosin University College of Medicine)
Lee, Sunggon (Department of Family Medicine, Kosin University College of Medicine)
Kim, Woomi (Department of Pharmacology, Kosin University College of Medicine)
Publication Information
Journal of Life Science / v.22, no.11, 2012 , pp. 1456-1462 More about this Journal
Abstract
Sorafenib is a multikinase inhibitor and an oral anticancer drug approved for the treatment of patients with advanced renal cell carcinoma and those with unresectable hepatocellular carcinoma. The purpose of this study was to develop an efficient method of the determination of sorafenib in human plasma using tandem mass spectrometry coupled with liquid chromatography (LC/MS/MS) and validate the method by the guidelines of the Korean Food and Drug Administration (KFDA). Plasma samples ($100{\mu}l$) were added with chlorantraniliprole as an internal standard and then mixed with the 0.1% formic acid-containing extraction solution composed of isopropyl alcohol and ethyl acetate (1:4, v/v). After centrifugation, the supernatant was concentrated at $45^{\circ}C$ under negative pressure and centrifugal force. The residue was reconstituted with a mobile phase and injected into the HPLC instrument using a reverse phase Waters XTerra$^{TM}$ C18 column (particle size $3.5{\mu}m$). Liquid chromatography was carried out within the run time of 5 min using a mobile phase composed of buffer (0.1% formic acid and 10 mM ammonium formate), methanol, and acetonitrile (1:6:3, v/v/v). The analytes were monitored by tandem mass spectrometry in the multiple reaction monitoring method programmed to detect sorafenib at 'm/z 465.2 ${\rightarrow}$ 252.5' and chlorantraniliprole at 'm/z 484.4 ${\rightarrow}$ 286.2' with positive electrospray ionization mode ($ES^+$). The result showed the proper linearity ($r^2$ > 0.99) over the range of 2,000-5,000 ng/ml with good accuracy (90.7-103.9%) and precision (less than 10%). The newly developed method using LC/MS/MS was validated by the guideline of KFDA and identified as more sensitive compared to the previous methods.
Keywords
Anticancer drug; sorafenib; chlorantraniliprole; LC; MS; MS; tandem mass spectrometry coupled with liquid chromatography;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Afify, S., Rapp, U. R. and Hogger, P. 2004. Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 809, 99-103.   DOI
2 Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R. M. 2007. Sorafenib in advanced clear-cell renal- cell carcinoma. N. Engl. J. Med. 356, 125-134.   DOI   ScienceOn
3 Hotte, S. J. and Hirte, H. W. 2002. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des. 8, 2249-2253.   DOI   ScienceOn
4 KFDA Guidance for Industry, Bioanalytical method validation, National Institute of Toxicology Department. 2003. http://www.kfda.go.kr/
5 Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D. and Bruix, J. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390.   DOI   ScienceOn
6 Park, D. J. and Kim, W. M. 2009. The rapid determination of gemcitabine by reversed-phase ultra-performance liquid chromatography. J. Life Sci. 19, 1698-1704.   DOI
7 Sparidans, R. W., Vlaming, M. L., Lagas, J. S., Schinkel, A. H., Schellens, J. H. and Beijnen, J. H. 2009. Liquid chromatography- tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 269-276.   DOI
8 Wilhelm, S. and Chien, D. S. 2002. BAY 43-9006: preclinical data. Curr. Pharm. Des. 8, 2255-2257.   DOI   ScienceOn
9 Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M. and Lynch, M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140.   DOI   ScienceOn
10 Zhao, M., Rudek, M. A., He, P., Hafner, F. T., Radtke, M., Wright, J. J., Smith, B. D., Messersmith, W. A., Hidalgo, M. and Baker, S. D. 2007. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 846, 1-7.   DOI